Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Trevor L Schell; Keith L Knutson; Sumona Saha; Arnold Wald; Hiep S Phan; Mazen Almasry; Kelly Chun; Ian Grimes; Megan Lutz; Mary S Hayney; Francis A Farraye; Freddy Caldera

doi:10.1093/ibd/izac082

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis. 2022 Nov 2;28(11):1781-1786. doi: 10.1093/ibd/izac082.

Authors

Affiliations

¹ Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
² Department of Immunology, Mayo Clinic Jacksonville, Jacksonville, FL, USA.
³ Department of Medicine, Division of Gastroenterology & Hepatology, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
⁴ Labcorp, R&D and Specialty Medicine, Burlington, NC, USA.
⁵ School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
⁶ Inflammatory Bowel Disease Center, Division of Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA.

No abstract available

Keywords: COVID-19 vaccine; Crohn’s disease; inflammatory bowel disease; ulcerative colitis.

Plain language summary

Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19*
Colitis, Ulcerative* / genetics
Humans
Inflammatory Bowel Diseases*
RNA, Messenger
mRNA Vaccines

Substances

COVID-19 Vaccines
RNA, Messenger